New York Life Investment Management LLC acquired a new stake in Glaukos Co. (NYSE:GKOS - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 5,656 shares of the medical instruments supplier's stock, valued at approximately $848,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. IFP Advisors Inc acquired a new position in Glaukos during the 4th quarter valued at about $43,000. Asset Planning Inc bought a new stake in Glaukos during the fourth quarter worth approximately $90,000. Harvest Fund Management Co. Ltd boosted its stake in Glaukos by 2,263.2% during the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock valued at $117,000 after buying an additional 860 shares in the last quarter. KBC Group NV grew its holdings in Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock worth $188,000 after acquiring an additional 201 shares during the period. Finally, Congress Asset Management Co. acquired a new stake in Glaukos in the 4th quarter valued at about $219,000. 99.04% of the stock is owned by institutional investors and hedge funds.
Glaukos Stock Up 0.9 %
GKOS stock traded up $0.94 during midday trading on Friday, reaching $104.14. The company had a trading volume of 1,370,823 shares, compared to its average volume of 797,237. The company has a 50 day moving average of $146.88 and a two-hundred day moving average of $138.89. The company has a market capitalization of $5.89 billion, a P/E ratio of -36.29 and a beta of 1.04. Glaukos Co. has a 1 year low of $84.08 and a 1 year high of $163.71. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19.
Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $105.50 million for the quarter, compared to analysts' expectations of $100.72 million. On average, equities research analysts expect that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.
Insider Activity at Glaukos
In related news, COO Joseph E. Gilliam sold 3,328 shares of the firm's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $149.85, for a total value of $498,700.80. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company's stock, valued at approximately $15,310,024.65. This trade represents a 3.15 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gilbert H. Kliman sold 2,000 shares of Glaukos stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total transaction of $288,020.00. Following the completion of the transaction, the director now directly owns 32,336 shares in the company, valued at approximately $4,656,707.36. This represents a 5.82 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,744 shares of company stock valued at $2,792,151. 6.40% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Several research firms recently commented on GKOS. Needham & Company LLC increased their target price on shares of Glaukos from $149.00 to $176.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Piper Sandler reiterated an "overweight" rating and set a $180.00 price objective (up previously from $140.00) on shares of Glaukos in a research report on Monday, January 27th. BTIG Research lifted their target price on Glaukos from $140.00 to $149.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. UBS Group assumed coverage on Glaukos in a report on Friday, December 6th. They set a "buy" rating and a $182.00 target price for the company. Finally, Wells Fargo & Company lifted their price target on Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $163.25.
View Our Latest Research Report on Glaukos
About Glaukos
(
Free Report)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Featured Articles
Before you consider Glaukos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.
While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
